ICOTYDE – Tuberculosis Testing in Patients with Plaque Psoriasis

SUMMARY

• Please refer to the local labeling for relevant information regarding ICOTYDE and tuberculosis (TB).
• Prior to initiating treatment with ICOTYDE, consider evaluating patients for TB infections based on clinical judgement.¹ 

PRESCRIBING INFORMATION

Indications and Usage¹ 

• ICOTYDE is an interleukin (IL)-23 receptor antagonist indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.

Warnings and Precautions - TB¹ 

• Based on clinical judgment, consider evaluating patients for TB infection prior to initiating treatment with ICOTYDE.
• In patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed, consider anti-TB therapy prior to initiating ICOTYDE.
• During and after ICOTYDE treatment, monitor patients for signs and symptoms of active TB.
• Avoid administering ICOTYDE to patients with active TB.

Medication Guide¹ 

• If patients have a history of TB or have active TB, healthcare providers may treat patients for TB before patients begin treatment with ICOTYDE.

Background

Blauvelt et at (2026)² published a joint position statement from the National Psoriasis Foundation (NPF) Medical Board and the International Psoriasis Council (IPC) regarding TB testing and IL-17 or IL-23 inhibitors.

• The following statement was formally adopted by both organizations: Routine testing for latent TB infection (LTBI) is not required prior to or during treatment of psoriasis patients with IL-17 or IL-23 inhibitors.² 
• This conclusion was based on an evidence review conducted by the commission evaluating the risk of progression from LTBI to active disease in patients receiving IL-17 or IL-23 inhibitors.² 
• This new joint position statement allows for exceptions, which may occur for specific patients and in certain clinical conditions.² 
  • For example, continued testing for LTBI may be prudent or warranted in areas of the world where TB is endemic or when patients are receiving concomitant medications, such as prednisone or other immunosuppressants, that may increase the risk of progression of LTBI to active disease.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 6 April 2026.